AYJ Fundamental Analysis - VALNEVA SE

Fundamental Rating

Overall AYJ gets a fundamental rating of 2 out of 10. We evaluated AYJ against 83 industry peers in the Biotechnology industry. AYJ has a bad profitability rating. Also its financial health evaluation is rather negative. AYJ is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

AYJ had negative earnings in the past year.
AYJ had a negative operating cash flow in the past year.
In the past 5 years AYJ always reported negative net income.
In multiple years AYJ reported negative operating cash flow during the last 5 years.

1.2 Ratios

AYJ has a Return On Assets (-26.86%) which is comparable to the rest of the industry.
AYJ has a Return On Equity (-80.02%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-26.86%
ROE	-80.02%
ROIC	N/A

ROA(3y)-15.85%

ROA(5y)-14.17%

ROE(3y)-50.34%

ROE(5y)-55.45%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AYJ's Gross Margin of 46.53% is in line compared to the rest of the industry. AYJ outperforms 44.58% of its industry peers.
In the last couple of years the Gross Margin of AYJ has declined.
The Profit Margin and Operating Margin are not available for AYJ so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	46.53%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.2%

GM growth 5Y-7.06%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AYJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AYJ has been increased compared to 1 year ago.
Compared to 5 years ago, AYJ has more shares outstanding
AYJ has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.72, we must say that AYJ is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AYJ (-0.72) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.89 indicates that AYJ is somewhat dependend on debt financing.
The Debt to Equity ratio of AYJ (0.89) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.89
Debt/FCF	N/A
Altman-Z	-0.72

ROIC/WACCN/A

WACC7.54%

2.3 Liquidity

AYJ has a Current Ratio of 1.78. This is a normal value and indicates that AYJ is financially healthy and should not expect problems in meeting its short term obligations.
AYJ has a Current ratio (1.78) which is comparable to the rest of the industry.
AYJ has a Quick Ratio of 1.36. This is a normal value and indicates that AYJ is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.36, AYJ perfoms like the industry average, outperforming 40.96% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.78
Quick Ratio	1.36

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for AYJ have decreased strongly by -1180.00% in the last year.
AYJ shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.89%.
The Revenue has been growing slightly by 6.09% on average over the past years.

EPS 1Y (TTM)-1180%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-271.43%

Revenue 1Y (TTM)19.89%

Revenue growth 3Y-21.31%

Revenue growth 5Y6.09%

Sales Q2Q%-35.76%

3.2 Future

The Earnings Per Share is expected to grow by 55.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, AYJ will show a quite strong growth in Revenue. The Revenue will grow by 17.00% on average per year.

EPS Next Y-664.71%

EPS Next 2Y-114.88%

EPS Next 3Y109.43%

EPS Next 5Y55.11%

Revenue Next Year-6.69%

Revenue Next 2Y2.34%

Revenue Next 3Y27.3%

Revenue Next 5Y17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AYJ. In the last year negative earnings were reported.
Also next year AYJ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as AYJ's earnings are expected to grow with 109.43% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-114.88%

EPS Next 3Y109.43%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AYJ!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

VALNEVA SE

FRA:AYJ (1/15/2026, 7:00:00 PM)

4.284

-0.16 (-3.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-20 2025-11-20/bmo

Earnings (Next)03-18 2026-03-18/amc

Inst Owners24.02%

Inst Owner ChangeN/A

Ins Owners0.21%

Ins Owner ChangeN/A

Market Cap368.07M

Revenue(TTM)274.97M

Net Income(TTM)-120.41M

Analysts81.82

Price Target6.56 (53.13%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-17%

Min EPS beat(2)-90.69%

Max EPS beat(2)56.68%

EPS beat(4)2

Avg EPS beat(4)-21.59%

Min EPS beat(4)-115.24%

Max EPS beat(4)62.87%

EPS beat(8)4

Avg EPS beat(8)-5.97%

EPS beat(12)6

Avg EPS beat(12)-29.73%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-5.23%

Min Revenue beat(2)-26.86%

Max Revenue beat(2)16.4%

Revenue beat(4)2

Avg Revenue beat(4)2.94%

Min Revenue beat(4)-26.86%

Max Revenue beat(4)26.97%

Revenue beat(8)3

Avg Revenue beat(8)-2.55%

Revenue beat(12)7

Avg Revenue beat(12)17.96%

Revenue beat(16)9

Avg Revenue beat(16)99.55%

PT rev (1m)-8.77%

PT rev (3m)-6.85%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-2.44%

EPS NY rev (1m)-3.34%

EPS NY rev (3m)-12.37%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-11.78%

Revenue NY rev (1m)-1.37%

Revenue NY rev (3m)-10.41%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.34
P/FCF	N/A
P/OCF	N/A
P/B	2.45
P/tB	2.89
EV/EBITDA	N/A

EPS(TTM)-0.64

EYN/A

EPS(NY)-0.32

Fwd EYN/A

FCF(TTM)-0.21

FCFYN/A

OCF(TTM)-0.21

OCFYN/A

SpS3.2

BVpS1.75

TBVpS1.48

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.86%
ROE	-80.02%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	46.53%
FCFM	N/A

ROA(3y)-15.85%

ROA(5y)-14.17%

ROE(3y)-50.34%

ROE(5y)-55.45%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.2%

GM growth 5Y-7.06%

F-Score4

Asset Turnover0.61

Health

		Industry Rank	Sector Rank
Debt/Equity	0.89
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	3.08%
Cap/Sales	0.22%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.78
Quick Ratio	1.36
Altman-Z	-0.72

F-Score4

WACC7.54%

ROIC/WACCN/A

Cap/Depr(3y)101.58%

Cap/Depr(5y)231.17%

Cap/Sales(3y)9.04%

Cap/Sales(5y)14.31%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-1180%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-271.43%

EPS Next Y-664.71%

EPS Next 2Y-114.88%

EPS Next 3Y109.43%

EPS Next 5Y55.11%

Revenue 1Y (TTM)19.89%

Revenue growth 3Y-21.31%

Revenue growth 5Y6.09%

Sales Q2Q%-35.76%

Revenue Next Year-6.69%

Revenue Next 2Y2.34%

Revenue Next 3Y27.3%

Revenue Next 5Y17%

EBIT growth 1Y-162.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-269.56%

EBIT Next 3Y56.42%

EBIT Next 5Y30.38%

FCF growth 1Y91.45%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y90.46%

OCF growth 3YN/A

OCF growth 5YN/A

VALNEVA SE / AYJ.DE FAQ

What is the fundamental rating for AYJ stock?

ChartMill assigns a fundamental rating of 2 / 10 to AYJ.DE.

What is the valuation status of VALNEVA SE (AYJ.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE (AYJ.DE). This can be considered as Overvalued.

How profitable is VALNEVA SE (AYJ.DE) stock?

VALNEVA SE (AYJ.DE) has a profitability rating of 1 / 10.

VALNEVA SE (AYJ.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VALNEVA SE / AYJ.DE FAQ

What is the fundamental rating for AYJ stock?

What is the valuation status of VALNEVA SE (AYJ.DE) stock?

How profitable is VALNEVA SE (AYJ.DE) stock?